RxDoctor Payments Data

Azra Farooqui, MD

Psychiatry · Springfield, VANPI 1366621351

Payments from drug & device makers

$2,599in general payments, 2019–2025

Across 130 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$956
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$375
  • AbbVie$309
  • Otsuka America Pharmaceutical, Inc.$219
  • Vanda Pharmaceuticals Inc.$196
  • Alkermes, Inc.$168
  • plus $376 from 5 others

What the payments were for

  • Food & beverage$2,34490%
  • Education$25510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,599 in reported general payments places this provider in the 85th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$11,247
Medicare patients
35
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate16$122,055
Invega SustennaPaliperidone Palmitate16$59,115
CaplytaLumateperone Tosylate28$50,906
VivitrolNaltrexone Microspheres12$32,221
VraylarCariprazine Hcl15$22,740
Paliperidone ErPaliperidone56$13,785
Fluphenazine Hcl39$11,210
TrintellixVortioxetine Hydrobromide11$5,700
Olanzapine50$5,656
Quetiapine Fumarate ErQuetiapine Fumarate27$3,645
Fluphenazine Decanoate34$3,417
Aripiprazole67$3,252
Divalproex Sodium ErDivalproex Sodium14$2,298
Quetiapine Fumarate63$1,722
Ziprasidone Hcl29$1,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$140$181,17132 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$375$50,90628 claims
Alkermes, Inc.Vivitrol$168$32,22112 claims
AbbVieVraylar$309$22,74015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Springfield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →